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The role of de novo mutations (DNMs) in common diseases remains largely unknown. Nonetheless, the rate of de novo deleterious
mutations and the strength of selection against de novo mutations are critical to understanding the genetic architecture of a disease.
Discovery of high-impact DNMs requires substantial high-resolution interrogation of partial or complete genomes of families via rese-
quencing.We hypothesized that deleterious DNMsmay play a role in cases of autism spectrum disorders (ASD) and schizophrenia (SCZ),
two etiologically heterogeneous disorders with significantly reduced reproductive fitness. We present a direct measure of the de novo
mutation rate (m) and selective constraints from DNMs estimated from a deep resequencing data set generated from a large cohort of
ASD and SCZ cases (n ¼ 285) and population control individuals (n ¼ 285) with available parental DNA. A survey of ~430 Mb of
DNA from 401 synapse-expressed genes across all cases and 25 Mb of DNA in controls found 28 candidate DNMs, 13 of which were
cell line artifacts. Our calculated direct neutral mutation rate (1.36 3 108) is similar to previous indirect estimates, but we observed
a significant excess of potentially deleterious DNMs in ASD and SCZ individuals. Our results emphasize the importance of DNMs as
genetic mechanisms in ASD and SCZ and the limitations of using DNA from archived cell lines to identify functional variants.Introduction
The rate at which human genomes mutate is critical to
understanding every aspect of medical, statistical, and
evolutionary genomics. To date, humanmutation rate esti-
mates have been indirectly inferred from a human-chim-
panzee divergence approach,1 from the analysis of muta-
tions causing human Mendelian diseases,2,3 or, more
recently, from next-generation sequencing in one nuclear
family.4 These data suggest that there will be ~2 de novo
mutations (DNMs) in the genome-wide coding regions
per zygote, so that such mutations may contribute to
some common diseases. Indeed, DNMs in individuals
with complex disorders could explain genetic factors that
are not detectable through genome-wide association
studies. Deep resequencing of trios or families (e.g.,
patients and their parents) suffering from various diseases
holds the promise of discovering DNMs that potentially
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to involve selectively constrained positions in which
mutations are likely to be less tolerated or may have
a substantial impact on fitness. If DNMs contribute signif-
icantly to a disorder, then there should be more functional
and potentially deleterious mutations (1) in cases versus
control samples and (2) in functionally constrained sites
versus nonfunctional, and thus unconstrained (neutral),
sites within the same cohort.
The disruption of gene function by rare deleterious pene-
trant mutations could represent an important cause of
neurodevelopmental disorders such as schizophrenia
(SCZ, MIM 181500) and autism spectrum disorders (ASD,
MIM 209850). In fact, deleterious DNMs may explain
observations such as the high global incidences of ASD
(~0.45%)5 and SCZ (~0.4%)6 despite extremely variable
environmental factors and reduced reproductive fitness,7
as well as increased risk with increasing parental age.8,9
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Table 1. Clinical Information for ASD and SCZ Individuals in which DNMs Were Confirmed
Sample Final Diagnosis Sex IQ Clinical Information Comorbidity
Familial History of
Psychiatric Illness
Age of Father
at Birth (yrs)
S00004 Autism disorder M NA ASQ1 score ¼ 23 None None 30
S00015 Asperger syndrome F NA No physical dimorphism.
ADI-R2 scores: social ¼ 17,
communication ¼ 13,
behavior ¼ 7
Moderate scoliosis,
hypopigmented
skin patch
None 27
S00036 Autism disorder M NA ADI-R scores: social ¼ 23,
communication ¼ 14,
behavior ¼ 4
None None 31
S00044 Autism disorder M NA ADI-R scores: social ¼ 24,
communication ¼ 10,
behavior ¼ 6
Minor anomaly:
skull broad and flat
on posterior aspect
None 40
S00096 Autism disorder M NA ASQ score ¼ 19 None None 38
S00161 Schizoaffective F 67 Childhood onset, age of
onset 11 yrs. Patient with
normal growth, no dysmorphic
feature, speech impairment,
and poor academic and social
performance. ASQ score ¼ 1
None Father has lifetime
depression and
compulsive behavior
NA
S00285 Schizoaffective M NA Schizoaffective disorder with
age of onset of 19 yrs
Mild mental
retardation
Parents are unaffected,
two brothers are
diagnosed with atypical
chronic psychosis
NA
S00215 Schizophrenia M NA No dysmorphic feature, moderate
to severe emotional withdrawal
None None 41
The following abbreviations are used: M, male; F, female; IQ, intelligence quotient; NA, not available.
1 ASQ: Autism Screening Questionnaire (score > 15 ¼ ASD).
2 ADI-R: Autism Diagnostic Interview-Revised (total cutoff score for the communication and language domain is 8 for verbal subjects and 7 for nonverbal subjects.
For all subjects, the cut off for the social interaction domain is 10 and the cut off for restricted and repetitive behaviors is 3).number variants (CNVs) in ASD and SCZ compared to
controls.10–12We hypothesized that sequencing of families
with affected individuals will identify an excess of
missense relative to silent de novo mutations and that
these mutations are candidate causal mutations for ASD
and SCZ. As part of the Synapse-to-Disease Project (S2D),
we resequenced synaptic genes in ASD and SCZ cases and
resequenced a subset of these genes in a group of popula-
tion controls. Such a resequencing project will capture
DNMs at greater resolution, with the potential to unambig-
uously identify missense or frameshift mutations not
detectable via linkage, association, or CNV methods. To
test our hypothesis, we examined variants identified by
resequencing 401 genes in a cohort of 285 ASD and SCZ
individuals and for a subset of 39 of these genes in 285
population control individuals. Our analyses demonstrate
a neutral mutation rate similar to that already reported and
an excess of de novo deleterious mutations associated with
the disease cohorts.Subjects and Methods
Diagnostic Screening and Selection of Patients
The cohort of patients used for the sequencing of candidate genes
for discovery of DNMs included 142 unrelated ASD patients (122
males and 20 females) as previously described,13 65% of whichThe Americanhad no family history of ASD or related neurological disorders.
All patients were diagnosed by using the Diagnostic and Statistical
Manual of Mental Disorders criteria (Table 1). Depending on the
recruitment site, the Autism Diagnostic Interview-Revised or the
Autism Diagnostic Observation Schedule was used. In addition,
the Autism Screening Questionnaire was completed for all the
subjects. We excluded patients with an estimated mental age
of<18months, a diagnosis of Rett syndrome, or Childhood Disin-
tegrative Disorder, as well as patients with evidence of any other
psychiatric and neurological conditions, including birth anoxia,
rubella during pregnancy, fragile-X syndrome, encephalitis,
phenylketonuria, tuberous sclerosis, Tourette syndrome, or West
syndrome. The 143 SCZ subjects (95 males and 48 females) were
collected from five different centers and included 28 cases of child-
hood-onset schizophrenia (COS) and 115 sporadic or familial
cases (with unaffected parents) of adult-onset schizophrenia or
schizoaffective disorder.14–17 Sixty percent of the SCZ subjects
had no family history of schizophrenia or other related neurolog-
ical disorders. They were evaluated by experienced investigators
who used the Diagnostic Interview for Genetic Studies (DIGS
3.0)18 or Kiddie Schedule for Affective Disorders and Schizo-
phrenia, as well as multidimensional neurological, psychological,
psychiatric, and pharmacological assessments. Family history for
psychiatric disorders was also collected by using the Family Inter-
view for Genetic Studies (FIGS). All DIGS and FIGS results were
reviewed by two or more psychiatrists for a final consensus diag-
nosis based on DSM-IIIR or DSM-IV at each center. Exclusion
criteria included patients with psychotic symptomsmainly caused
by alcohol, drug abuse, or other clinical diagnosis includingmajorJournal of Human Genetics 87, 316–324, September 10, 2010 317
cytogenetic abnormalities. We selected patients for which blood
DNA was available so that DNMs could be validated and for
which DNAwas available from both parents to test for inheritance
of the variants. The population control cohort (150 males and 135
females) consistedofunrelated individuals collected for theQuebec
Newborn Twin Study (QNTS),19 in which DNA samples were
available from both parents and both twins (either monozygotic
or dizygotic); however, only one sibling was chosen randomly for
sequencing. All samples were collected through informed consent
following approval of each of the studies by the respective institu-
tional ethics reviewcommittees. Ethnic origins of the grandparents
were self-reported by the parents of probands and population
control subjects. The ASD cohort is composed of FrenchCanadians
(85), other EuropeanCaucasians (54), and non-Caucasians (3). The
SCZ cohort is composed of European Caucasians (136) and Asians
(7). The control population is composed of French Canadians
(204), other European Caucasians (55), non-Caucasians (18), and
individuals of mixed origin (8).
Selection of Candidate Genes
The list of genes screened in the S2D project was generated from
a repertoire of approximately 5000 potential synaptic genes
compiled from several synaptic lists from different synapse data-
bases, including the Genes-to-Cognition (G2C) database (which
includes an extensive list of postsynaptic genes)20 and the Synapse
database (SynDB, which uses Synapse Ontology algorithms to
mine potential synaptic genes),21 and from an extensive list
of synaptic vesicle genes.22 It also comprises genes identified
through manual searches of PubMed that are either localized at
the synapse or affect synapse-related functions (i.e., plasticity,
axon or dendrite outgrowth, dendritic spine morphology, learn-
ing, and memory).
The sequencing data reported here were generated, using Sanger
technology, from the screening of the coding regions and splice
site junctions of 122 X-linked and 279 autosomal potentially
synapse-related genes (see Table S1 available online) in 142 ASD
and 143 SCZ subjects. The excess of X-linked genes is due to the
S2D selection procedure, which sought to include all potentially
synaptic X-linked genes because of their importance in neurodeve-
lopmental diseases23 and because ASD is more common in males
than females.24 The genes on the autosomes were largely ones
that encode glutamate receptors (including NMDA receptors,
AMPA receptors, kainate receptors, and metabotropic glutamate
receptors), as well as genes that encode proteins that interact
with them, in particular those complexed with the NMDAR,
a majority of which were identified by large proteomic studies25
and reported in the G2C database.20 The autosomal gene list is
composed of 203 genes from the glutamate receptor complex
(23 known glutamate receptors and 180 of their synaptic interac-
tors) and 73 genes implicated in synapse function and/or cogni-
tion, interaction with ASD genes, or because of their disruption
in the context of small CNVs or balanced translocations in
patients with ASD, SCZ, or mental retardation. An additional three
genes were included for which mutations were reported to cause
ASD, SCZ, or the related neurodevelopmental disease, nonsyn-
dromic mental retardation, which is known to coexist with ASD.
Mutations in which multiple reports have previously found asso-
ciations with diseases that are not related to ASD or SCZ were elim-
inated. In addition, data generated from the resequencing of 39 of
these 401 genes in 285 population control samples were used. The
39 genes were resequenced in controls after discovering a de novo
or deleterious mutation in ASD or SCZ samples.318 The American Journal of Human Genetics 87, 316–324, SeptembDNA Preparation, Sequencing, and Variant
Identification
Genomic DNA was extracted from peripheral blood lymphocytes
and/or lymphoblastoid cell lines with Puregene extraction kits
(Gentra System). A panel of seven microsatellite markers was
used to confirm parentage for all samples.26 To overcome the issue
of limited DNA material, we performed the gene screening on
DNA isolated from an Epstein-Barr virus transformed lymphoblas-
toid cell line for most cases (n¼ 224). The rest were done on blood
DNA (n ¼ 61). The ASD cell line samples had been frozen or
regrown a maximum of two times. For the SCZ cell lines, 59
DNA samples were acquired fromCoriell and are available through
a request to J.L.E.D. All unique variants (heterozygous in a single
individual) detected during the screen were tested in the parents’
DNA. All potential de novo variants (not seen in the parents)
were reconfirmed by reamplifying the fragment and resequencing
the proband blood DNA and both his/her parents with reverse and
forward primers in order to eliminate PCR or sequencing artifact.
All de novo variants identified originally from cell line DNA
were retested in the subject DNA extracted from blood to rule
out variations that could have occurred during production or
growth of the lymphoblastoid cell line. An identity DNA test
was performed to eliminate any cell lines and/or blood inconsis-
tencies caused by sample identification errors or nonpaternity.
Primers were designed with the Exon Primer program from the
UCSC Genome Browser. PCR products were sequenced on one
strand with Sanger technology, done at the GenomeQuebec Inno-
vation Centre on a 3730XL DNA Analyzer System. PolyPhred
(v. 5.04), PolyScan (v. 3.0), and Mutation Surveyor (v. 3.10,
SoftGenetics) were used for variant detection.
Estimation of Base Pairs Screened
To estimate the number of base pairs (bp) screened, we determined
the amount of coding and noncoding (intronic, UTR) sequence
screened for each gene based on our PCR amplicon designs
(Table S2). Briefly, genomic intervals were calculated based on
forward and reverse PCR primer sequences for each amplicon.
Because the DNA sequence overlapping each PCR primer is not
surveyed, these genomic intervals did not include those corre-
sponding to each PCR primer. Furthermore, because the first
~30 bp of sequence from each sequence read are of low quality, we
trimmed 30 bp from each genomic interval (usually at the forward
primer end). Overlapping amplicons were merged to form a single
genomic interval. Then each genomic interval was annotated as to
coding and noncoding sequence for each gene with tools available
on the refGene table from the UCSC Genome Browser.
We defined functional and nonfunctional sites sequenced as
those in which a nucleotide change would or would not lead to
an altered protein sequence, respectively. We estimated that
71.2% of coding sites were functional, whereas nonfunctional
sites were estimated at 28.8% of the coding and 100% of the
intronic sites.27 The number of CpG sites was estimated as 2.8%
for functional sites and 1% for nonfunctional sites.28 The correc-
tions for increased mutation rates in CpG regions was 103 the
number of CpG sites, yielding an effective bases sequenced of 10
3 CpG sites þ non-CpG sites for both functional and nonfunc-
tional sites.
Evaluation of False-Negative Mutation Calls
A subset of 71 of our ASD samples was also genotyped by Affyme-
trix 500K arrays. We tested our ability to detect heterozygous vari-
ants by comparing our heterozygous calls from the resequencinger 10, 2010
Table 2. De Novo Mutations Discovered by Resequencing 458,877,850 Nucleotides of DNA in ASD, SCZ, and QTNS Control Individuals
Gene
Sample
and Ref. Diagnosis
Mutation
Type
Mutation
Location Chr. Position
Nucleotide Change
and Genomic Context
Amino Acid
and/or
Structural
Change
MAPP
p Value
SHANK3 S00004 Autism
disorder
INDEL CODING 22 49500342 CGAGATTAGC(G/-)TAAGGGCCAC Splice
site delG
–
IL1RAPL1 S00015 Asperger
syndrome
INDEL CODING X 29869731 CTTGGTGCTA(TACTCTT/-)GCTGCTTGTA I367SfsX6 –
GSN S00099 Asperger
syndrome
INTRONIC INTRONIC 9 123104277 GTGAGGCTGG(C/G)CCTGCCCAGC Within
intron
–
KLC2 S00036 Autism
disorder
MISSENSE CODING 11 65788196 TACTATCGGC(G/C)GGCACTGGAG R349P 0.001
KIF5C S00044 Autism
disorder
MISSENSE CODING 2 149575030 GGACCGTAAG(C/T)GCTACCAGCA R802C,
R872C
0.001
FLJ16237 S00096 Autism
disorder
MISSENSE CODING 7 15393678 CCATCACTTA(T/C)TTTCCATATG F279L 0.472
NRXN1 S02959 Schizophrenia INDEL CODING 2 50002821 CAGCACACGG(-/ACGG)GTATGGTCGT G1402DfsX29 –
MAP2K1 S00237 Schizophrenia INTRONIC INTRONIC 15 64561310 CTTCTTGTAC(G/T)GTCAGGGAGA Within
intron
–
SHANK3 S00161 Childhood-onset
Schizophrenia
MISSENSE CODING 22 49484091 GCATGACACA(C/T)GGCCTGGTGA R536W 0.051
GRIN2B S05650 Paranoid
Schizophrenia
MISSENSE CODING 12 13611351 CTTCTACATG(T/G)TGGGGGCGGC L825V <0.001
SHANK3 S00285 Schizoaffective,
mild mental
retardation
NONSENSE CODING 22 49506476 TGCCCGAGAG(C/T)GAGCTCTGGC R1117X –
KIF17 S00215 Schizophrenia NONSENSE CODING 1 20886681 GGAGCAGATA(C/A)TTCCTGGATG Y575X –
BSN S00237 Schizophrenia SILENT CODING 3 49666988 GCACTGCAGT(G/C)GTAGACCTCC V1665V –
ATP2B4 S00182 Disorganized
Schizophrenia
SILENT CODING 1 201935404 TCATCCGAAA(C/T)GGTCAACTCA N195N –
SHANK3 S04261 QNTS, unknown MISSENSE CODING 22 49507364 GCCACCAGTG(C/T)CTCCCAAGCC P1429S 0.107screen of these 71 samples with calls made for overlapping geno-
typed SNPs on the array (Table S3). Of the 1649 heterozygous calls
made in 90 autosomal SNPs on the Affymetrix 500K chip overlap-
ping our screened amplicons, we failed to detect 41 of those
heterozygous calls in our resequencing survey, suggesting that
our false-negative rate is ~2%.Prediction of Missense Severity
The potential consequence of eachmissense variant was evaluated
with the MAPP,29 PolyPhen,30 SIFT,31 and PANTHER32 programs.
Orthologous protein sequence alignments were obtained with
tools available on the Galaxy Browser website for the generation
of MAPP scores.Statistical Analysis
Excess of functional relative to nonfunctional DNMs in each cate-
gory (initial, CpG, non-CpG, and effective bases sequenced) was
measured via (1) binomial test (P[X R number of functional
DNMs j q, functional bases sequenced], where q ¼ neutral muta-
tion rate) and (2) Fisher’s exact test (FET). Functional DNMs are
defined as missense and nonsense DNMs, whereas nonfunctional
DNMs include silent and intronic DNMs.The AmericanResults
Identification of De Novo Mutations
By resequencing the coding and splice junction regions of
401 genes in 142 ASD and 143 SCZ samples (and 19 of
these genes in 285 Quebec Newborn Twin Study [QNTS]
samples), we identified 6184 DNA variants. Of these,
2437 were unique (i.e., heterozygous in 1 of 285 unrelated
individuals tested). Each of these 2437 unique variants was
resequenced in the proband and both parental samples to
determine inheritance mode (transmitted versus de novo).
A total of 15 unique variants was confirmed in the proband
blood DNA sample but not detected in either parents’
blood DNA sample (Table 2). These 15 validated DNMs
are either germline-derived mutations or arose as somatic
mutations in blood tissue. A further 13 variants were not
detected in parents’ DNA, nor were they detected in the
proband blood DNA sample, and they were assumed to
be generated during lymphoblastoid cell line development
(Table 3).
Of the 15 confirmed DNMs, 14 were detected in the ASD
and SCZ cohorts (2 nonsense, 5 missense, 3 frameshiftingJournal of Human Genetics 87, 316–324, September 10, 2010 319
Table 3. Cell Line Mutations Not Observed in the Blood Sample of Patients
Gene Sample Status
Mutation
Type
Mutation
Location Chr. Position
Nucleotide Change
and Genomic Context
Amino Acid
Change
Cell Line
Origin
WWC1 S00056 AUT SILENT INTRONIC 5 167788404 CAGAAGGAAC(G/A)GTCTGTGTGG – UMontreal
PLCB1 S00068 AUT MISSENSE CODING 20 8585862 GATTTCACTC(C/T)AGAAGTGTAC P209L UMontreal
PLXNB3 S00009 AUT MISSENSE CODING X 152694010 GGTGACCTGG(C/T)GGCCCATTAC A1431V UMontreal
DRP2 S00093 AUT MISSENSE CODING X 100383370 AAGCAGGCGA(C/T)GGTGGCCAGT T203M UMontreal
PSMD10 S00016 AUT SILENT CODING X 107217953 TTGCGGCTTC(T/A)GCTGGCCGGG S82S UMontreal
MCF2 S00204 SCZ SILENT INTRONIC X 138512219 TACAGTAATT(A/C)TTCAAGTATT – Krebs
SLC7A3 S00218 SCZ INDEL INTRONIC X 70064365 CAGGTCAGTAT(-/A)CAAATGTTTG InsA 30 of exon UMontreal
CAMK2A S00191 SCZ MISSENSE CODING 5 149598465 CGAGGATGAA(G/A)ACACCAAAGG D342N, D353N UMontreal
GRPR S00264 SCZ MISSENSE CODING X 16080316 TCCCGGAAGC(G/T)ACTTGCCAAG R261L DeLisi/Coriell
ADAM22 S00193 SCZ MISSENSE CODING 7 87660477 AAAGTGAACC(G/A)ACAAAGTGCC R860Q, R889Q,
R896Q
UMontreal
ARHGAP6 S00261 SCZ MISSENSE CODING X 11592643 GAGAGTCTCG(G/A)CCCTCGCTTG G76D UMontreal
ADD2 S00067 SCZ NONSENSE CODING 2 70744118 AAAGAAATTC(C/T)GAACCCCCTC R404X, R710X UMontreal
RPS6KA6 S00274 SCZ SILENT CODING X 83206731 ATCAGCGGTA(T/C)ACTGCTGAAC Y672Y DeLisi/Coriellindel, 2 silent, and 2 intronic DNMs) and 1 was a missense
DNM found in the population control group (Table 2). Five
of the 11 point mutations in cases were transitions, four
were CpG mutations, and six were transversions. Eight of
the 14 DNMs detected among ASD and SCZ samples
were disruptive to translation or protein structure and/or
function, including three frameshift and two nonsense
DNMs, and three missense DNMs were predicted to signif-
icantly disrupt protein structure via the computational
predictionmethodMAPP.33 SignificantMAPP scores reflect
a potentially damaging amino acid change and predict
deleterious consequences. Reassuringly, MAPP scores relate
to allele frequencies as would be predicted by population
genetics, with increasingly deleterious alleles tending
toward lower frequencies (Figure S1). Three MAPP p values
of DNMs in SCZ and ASD samples are significantly low
(Table 2); two were found in kinesin-encoding genes
(R349P in KLC2 [MIM 611729] and R802C in KIF5C
[MIM 604593]). One nonsense mutation (Y575X) was
also found in a kinesin-encoding gene (KIF17 [MIM
605037]). One nonsense and one splice site deletion were
found within SHANK3 (MIM 606230), and a frameshift
mutation was found in each of IL1RAPL1 (MIM 300206)
and NRXN1 (MIM 600565). We have also confirmed the
damaging predicted functional impact of the five de
novo missense mutations via three other prediction
programs (PANTHER, SIFT, and PolyPhen) (data not
shown). Only one DNM was discovered in an X-linked
gene (IL1RAPL1).12 More detailed description of these
genes and their potential role in ASD and SCZ will be pre-
sented elsewhere (unpublished data).
Estimates of the Neutral Human Mutation Rate
To calculate human mutation rates, we estimated the total
initial count of bases we resequenced in all cohorts as320 The American Journal of Human Genetics 87, 316–324, Septemb458.8 Mb (Table 4; Subjects and Methods). This includes
230.6 Mb of protein-coding and 228.3 Mb of intronic
sequence. In the ASD and SCZ cohorts, exonic material
sequenced is 215,186,702 bases and intronic is
218,145,769 bases. The total number of replacement sites
in the cases is 153,704,787 and the number of silent
(synonymous and intronic) sites is 279,627,684. In the
QNTS cohort, 15,422,960 bases were exonic and
10,122,419 bases were intronic. The number of replace-
ment sites is 11,016,400 and the number of silent sites is
14,528,979.
We distinguished functional from nonfunctional sites
based on the effect of a mutation on transcription or trans-
lation of the protein at a given position (see Subjects and
Methods). When addressing whether there was an excess
of functional DNMs34 relative to nonfunctional or silent
base pairs, we calculated the ‘‘effective bp count.’’35
Because mutations are 10 times more likely to occur at
CpG sites than at non-CpG sites, we calculated the total
number of CpG and non-CpG sites for both functional
and nonfunctional sites28 and calculated the effective bp
count (non-CpG sites þ 10 3 CpG sites) to account for
increased mutation rates in CpG sites (Table 4).
We calculated the neutral mutation rate by examining
the number of DNMs found in nonfunctional sites in our
ASD, SCZ, and QNTS samples. In total, we sequenced
~294 Mb of nonfunctional DNA, in which we observed
four DNMs (Table 2; in genes GSN [MIM 137350],
MAP2K1 [MIM 176872], BSN [MIM 604020], and ATP2B4
[MIM 604020]). Because these mutations are unlikely to
be pathogenic (referred to here as ‘‘neutral’’), they allowed
us to directly estimate the rate of neutral point mutations.
We estimated this to be 1.36 3 108 mutations per site per
generation (95% Poisson confidence interval: 0.34 3 108,
2.7 3 108). These estimates of neutral mutation rates areer 10, 2010
Table 4. Base Pairs and DNMs Surveyed among ASD and SCZ Trios with No Family History
Site and Mutation Class Initial Counta CpGb Non-CpG Effective Countc
Functional Nonsynonymous bases 96,065,492 2,689,834 93,375,658 120,273,996
Nonsynonymous DNMs 6 3 3 6
Neutral Synonymous bases 61,481,915 1,721,494 59,760,421 76,975,357
Intronic bases 218,145,769 2,181,458 215,964,311 237,778,888
Silent (synonymous and intronic) DNMs 4 2 2 4
p value One-tail binomial testd 0.003 0.161 0.031 0.008
Fisher’s exact test 0.022 0.4041 0.1067 0.032
a All statistics are calculated with base pairs and DNMs calculated for only trios with unaffected families.
b Estimated 2.8% of initial coding sites and 1% of initial intronic sites are CpG sites.
c To account for increased mutation rates: (non-CpG sites) þ (10 3 CpG sites).
d P(3R number of functional DNMs j nonfunctional rate).
Table 5. Comparisons of Constraint for Genes Expressed at the
Synapse in the ASD and SCZ Cohort
Functional Nonfunctional
Functional:
Nonfunctional p Value
Point and
indel DNMs
10 4 2.5 –
Unique SNPs 785 1652 0.48 0.003a
All SNPs 1306 4878 0.27 <0.001a
Shown are the counts of point and indel mutations or segregating SNPs for the
different categories of variation.
a p value is the result of Fisher exact test comparisons for DNMs versus the two
allele frequency classes of SNPs (unique or all).similar to, and not significantly different from, the esti-
mate of 2.5 3 108 derived from phylogenetic analyses1,2
and the intergeneration estimate of 1.1 3 108 derived
from next-generation sequencing data.4
Excess of Functional DNMs in ASD and SCZ Cohorts
If DNMs cause sporadic cases of ASD and SCZ, then DNMs
will be more common in functional than in nonfunctional
sites in our disease cohorts. Based on an observation of four
DNMs in 294 Mb of neutral (silent and intronic) DNA, we
expect 1.3 DNMs in the 96 Mb of nonsynonymous DNA
sites to be resequenced in the cases with no family history
of disease (65% of ASD cases and 60% of SCZ cases).
However, among trios without family histories (Table 1),
we observed six nonsynonymous DNMs surveyed in indi-
viduals, representing a significant enrichment of nonsy-
nonymous DNMs (p ¼ 0.003 in one-tail binomial test;
p ¼ 0.022 FET; Table 4). This excess remains significant
even when we take into account that CpG dinucleotides
mutate faster than other sites and are more common in
exons than introns (p ¼ 0.008 in one-tail binomial test;
p ¼ 0.032 FET; see Table 4 and Subjects and Methods).
If DNMs cause disease, we also expect point mutations
with larger effects to be more frequent than expected in
the disease group. Among our five nonsynonymous
DNMs in trios with no family history, two are nonsense
mutations (ratio 1:2.5), similar to previous estimates3 for
DNMs causing Mendelian diseases (1:3.9) that are cata-
loged in the Human Gene Mutation Database (HGMD).
Also, the ratio of synonymous to missense DNMs in the
ASD and SCZ cohort is similar to that observed for
HGMD.3 Under a neutral model,3 we would expect a ratio
of 1 nonsense to 19.7 missense DNMs3 when only point
mutations are considered. In HGMD, the number of
missense to nonsense DNMs was significantly higher
than the neutral expectation. Using a binomial test, our
observed number of missense to nonsense DNMs was
also significantly higher than the neutral expectation
(p ¼ 0.04), suggesting that some of the mutations are pre-
disposed to be pathogenic. All of these observationsThe Americansuggest an excess of potentially disease-predisposing
DNMs in the SCZ and ASD cohort. Taken together, these
lines of evidence suggest that mutations with functional
effects are overrepresented within the synapse genes
sequenced in individuals showing sporadic ASD and SCZ.Comparing DNMs and Segregating Variant Ratios
Functional and nonfunctional segregating variants
provide an expectation of the proportion of functional
and nonfunctional DNMs. We compared the ratio of func-
tional and nonfunctional DNMs to the ratios of the same
classes of segregating variants in the ASD and SCZ cohorts
(Table 5). Similar observations were found for the QNTS
cohort. The comparison was significant when the func-
tional and nonfunctional DNMs were compared to all
segregating sites (FET, p< 0.001) and to unique SNP classes
in the ASD and SCZ cohort (FET, p¼ 0.003). Given that the
ratio of functional to nonfunctional was two times higher
for DNMs relative to segregating sites, this suggests an
excess of deleterious DNMs. Furthermore, given that rare
SNP classes are likely enriched for slightly deleterious
missense mutations,3 this significant comparison can be
considered conservative. Under the expectation that
most highly deleterious mutations will be selectively
removed in one generation, the unique comparisons aboveJournal of Human Genetics 87, 316–324, September 10, 2010 321
provide insight into the proportion of deleterious muta-
tions in humans that are selectively removed relative to
segregating variation. Potentially disease-causing DNMs
were more frequent than nonfunctional DNMs in our
cohorts relative to expectations inferred from segregating
mutations.Discussion
In the present study, we have attempted to directly esti-
mate the mutation rate with a large set of resequencing
data generated from a common disease-based project. In
addition, we have tried to validate that DNMs are a possible
genetic factor of ASD and SCZ. There are three main
conclusions that can be drawn from our study. First, the
source of biological material (blood DNA versus cell line
DNA) is crucial while doing experimental analyses with
resequencing data seeking DNMs. All DNMs analyzed
here were confirmed by resequencing, via standard Sanger
technology, from DNA samples extracted from blood in
the proband and in the parents. In so doing, we discovered
that ~50% of our identified DNMs are the result of muta-
tions that most likely occurred during the transformation
and propagation of lymphoblastoid cell lines, thus
creating false-positive DNMs. This observation was also
recently stressed in CNV analyses by The Wellcome Trust
Case Control Consortium.36 This biological artifact, if
unnoticed, would have significantly biased our results
and would have contributed to a doubling of mutation
rates for all classes of sites. Interestingly, 8 of 13 cell line
mutations were X-linked, suggesting that this chromo-
some is particularly susceptible to the generation or accu-
mulation of deleterious mutations after transformation of
lymphoblasts with Epstein-Barr virus. These mutations,
which are hemizygous in males, may also be positively
selected because they contribute to higher fitness in cells
carrying these mutations. An awareness of the high rate
of mutation observed in cell lines, some of which are
archived at the Coriell Institute, is critical to any large-scale
whole-genome sequencing project, and potentially to
those taking advantage of next-generation sequencing
technologies, to capture rare and/or pathogenic muta-
tions. Not only will the inherent error rate of the technol-
ogies be critical, but so, too, will the choice of samples and
the way those samples are being maintained or cultured.
Second, by using a direct calculation and classical Sanger
sequencing, we validated the reported estimates of the
neutral mutation rate in humans. Third, our study
confirms the critical role that large-sample, high-resolu-
tion nucleotide surveys play in detecting potentially
disease-causing DNMs.
We acknowledge that there are some weaknesses in our
present study. The amount of resequencing in the controls
is substantially lower than the resequencing in the cases.
In fact, direct comparison in terms of sequences covered
between cases and controls would be the optimal way to322 The American Journal of Human Genetics 87, 316–324, Septembdirectly estimate the rate of mutation and detect signifi-
cant differences in mutation rate between the cases and
controls. Nevertheless, our analyses show that the rate of
potentially deleterious DNMs is significantly higher in
functional compared to nonfunctional sites within the
disease cohorts, suggesting a role of functional DNMs in
the etiology of ASD and SCZ. Given that our estimate of
the neutral human mutation rate is consistent with
a recent genome-wide estimate4 and the accumulation of
more direct observations of mutation, the confidence
intervals of mutation rate estimates will begin to narrow.
The rate of functional mutations in this survey is almost
five times that of neutral or genome-wide rates, supporting
our conclusions that we have likely detected mutations
that are causal with respect to ASD and SCZ. By resequenc-
ing the genes in which DNMs were discovered among
QNTS (random) participants, we were able to validate
that these genes, among a substantial number of random
individuals, do not carry functional DNMs, with the excep-
tion of one locus (SHANK3, Table 2). At SHANK3, a nonsy-
nonymous mutation of low predicted functional impact
was discovered in the QNTS cohort. SHANK3 has been
previously implicated in ASD37 and may be a rapidly
evolving gene in humans, with substantial neurological
phenotypic impact.
By demonstrating that functional DNMs are at higher
relative frequencies than segregating polymorphisms
(Table 5), we show that DNMs may have a substantial
role in ASD and SCZ etiology. The power of the genomics
approaches employed here is that DNMs are not subject
to the same demographic processes that shape segregating
site variation. As a result, it is not necessary to test or
correct for population structure, nor are our analyses
subject to population stratification or admixture issues
associated with GWAS analyses. By using a simple geno-
mics approach that compares different classes of sites, we
have sufficient power to map candidate mutations that
are more likely to contribute to these diseases.
From sequencing only 8% of genes expressed in the
synapse, functional DNMswere found in 5% of individuals
with no family history, exhibiting a wide range of clinical
phenotypes (see Subjects and Methods and Table 1).
Although we biased our sampling strategy toward likely
candidate genes, our predictions appear to have been
poor regarding the X chromosome. It is therefore possible
that by sequencing all 5000 synapse-related genes, we may
uncover many of the mutations responsible for sporadic
cases of ASD and SCZ. Furthermore, because nonfunc-
tional DNMs are predicted to be relatively rare in ASD
and SCZ genes (1.36 3 108 nonsynonymous DNMs
per site), it may be easy to determine the likely causative
mutations.Supplemental Data
Supplemental Data include one figure and four tables and can be
found with this article online at http://www.cell.com/AJHG/.er 10, 2010
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